Evaluation of the safety in the combination usage of Cerdelga and Cerezyme in type III Gaucher disease patients and the efficacy on soft tissue diseases.

• This is a 3-year study and the enrollment time of this study is 24 months.
• The participants have to receive the investigational agent:Cerdelga.(Cerdelga have 21 mg、42 mg and 84 mg capsule.)
• The participants have to go back to the hospital and receive the investigational agent and take the Gaucher related biomarkers test before receiving Cerdelga, and 2 weeks, 1, 3, 6, 12, 18 and 24 months after receiving Cerdelga.
• The participants have to inform if any adverse events happened.
• The investigators will follow up by phone if adverse events happened in the participants after one months start the treatment.

Inclusion Criteria:

• Gaucher disease patients diagnosed by low B-glucocerebrosidase deficiency and GBA mutation .
• The participant is at least 6 years old at time of enrollment.
• Under stable Cerezyme dosage for at least for 3 months.
• Presence of lymphadenopathy.
• Patient (and/or their parent/legal guardian) is willing to participate and able to provide signed informed consent.

Exclusion Criteria:

• The participant is CYP2D6 ultra-rapid metabolizer.
• The participant had received substrate reduction therapy for Gaucher disease within 3 months of enrollment.
• The participant had any clinically significant disease other than GD, including cardiovascular (especially arrhythmia), renal, liver, pulmonary, endocrinopathy, hypokalemia, or hypomagnesemia that may confound the study result.
• The participant is pregnant or lactating.
• The participant is known to be allergy to Cerdelga.
• The participant use drugs that will strongly inhibit CYP2D6 or CYP3A activity .